Skip to main content

Table 3 Hazard ratios (95% CI) associated with delays in treatment intensification by 1 year in interaction with poor glycaemic control [HbA1C ≥7% (≥53 mmol/mol) and HbA1C ≥7.5% (≥58 mmol/mol)] consistently during 1 year post diagnosis of diabetes for cardiovascular events

From: Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes

 

Without previous CVD HR (95% CI)

P

With previous CVD HR (95% CI)

P

All patients HR (95% CI)

P

MI

 With HbA1C ≥7% (≥53 mmol/mol)

  A: IT within 1 year

1.37 (1.09, 1.72)

<0.01

1.21 (0.81, 1.82)

0.36

1.32 (1.08, 1.61)

<0.01

  B: IT after 1 year

1.80 (1.45, 2.22)

<0.01

1.34 (0.91, 1.96)

0.13

1.67 (1.39, 2.01)

<0.01

 With HbA1C ≥7.5% (≥58 mmol/mol)

  A: IT within 1 year

1.59 (1.27, 1.99)

<0.01

1.12 (0.73, 1.71)

0.62

1.47 (1.20, 1.79)

<0.01

  B: IT after 1 year

1.56 (1.24, 1.97)

<0.01

1.42 (0.95, 2.14)

0.09

1.52 (1.24, 1.86)

<0.01

HF

 With HbA1C ≥7% (≥53 mmol/mol)

  A: IT within 1 year

1.14 (0.94, 1.40)

0.19

1.52 (1.09, 2.12)

0.015

1.23 (1.04, 1.46)

0.017

  B: IT after 1 year

1.63 (1.36, 1.96)

<0.01

1.66 (1.21, 2.27)

<0.01

1.64 (1.40, 1.91)

<0.01

 With HbA1C ≥7.5% (≥58 mmol/mol)

  A: IT within 1 year

1.32 (1.07, 1.62)

<0.01

1.52 (1.08, 2.13)

0.016

1.37 (1.15, 1.63)

<0.01

  B: IT after 1 year

1.61 (1.32, 1.97)

<0.01

1.50 (1.06, 2.12)

0.021

1.58 (1.33, 1.88)

<0.01

Stroke

 With HbA1C ≥7% (≥53 mmol/mol)

  A: IT within 1 year

1.28 (1.03, 1.60)

0.025

1.80 (1.10, 2.95)

0.019

1.36 (1.12, 1.66)

<0.01

  B: IT after 1 year

1.50 (1.22, 1.84)

<0.01

1.60 (0.98, 2.60)

0.06

1.51 (1.25, 1.83)

<0.01

 With HbA1C ≥7.5% (≥58 mmol/mol)

  A: IT within 1 year

1.27 (1.01, 1.59)

0.040

1.89 (1.16, 3.06)

0.010

1.36 (1.11, 1.67)

<0.01

  B: IT after 1 year

1.37 (1.09, 1.71)

<0.01

1.34 (0.78, 2.30)

0.28

1.36 (1.11, 1.67)

<0.01

Any CVE

 With HbA1C ≥7% (≥53 mmol/mol)

  A: IT within 1 year

1.22 (1.07, 1.38)

<0.01

1.36 (1.06, 1.74)

0.015

1.24 (1.11, 1.40)

<0.01

  B: IT after 1 year

1.64 (1.45, 1.85)

<0.01

1.57 (1.25, 1.98)

<0.01

1.62 (1.46, 1.80)

<0.01

 With HbA1C ≥7.5% (≥58 mmol/mol)

  A: IT within 1 year

1.32 (1.15, 1.50)

<0.01

1.40 (1.09, 1.81)

<0.01

1.33 (1.19, 1.50)

<0.01

  B: IT after 1 year

1.50 (1.32, 1.71)

<0.01

1.50 (1.17, 1.94)

<0.01

1.50 (1.33, 1.68)

<0.01

  1. The reference group was those with TTIT <12 months and HbA1c <7 or 7.5% (<53 or 58 mmol/mol). A: TTIT <12 months and HbA1c ≥7 or 7.5% (≥53 or 58 mmol/mol), B: TTIT ≥12 months and HbA1c ≥7 or 7.5% (≥53 or 58 mmol/mol). Analyses are based on multivariate Cox-regression models, with contrast matrix to evaluate the effect of delay in treatment intensification in conjunction higher and lower levels of HbA1c at 7 and 7.5% cut offs (53 and 58 mmol/mol).
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840